We are live on ! Find out more
GC

Grimes & Company Portfolio holdings

AUM $4.62B
1-Year Est. Return 29.71%
This Fund
S&P 500
This Quarter Est. Return
+5.43%
1 Year Est. Return
+29.71%
3 Year Est. Return
+66.17%
5 Year Est. Return
+73.59%
10 Year Est. Return
+287.63%
AUM
$2.44B
AUM Growth
+$71.4M
Cap. Flow
-$5.26M
Cap. Flow %
-0.22%
Top 10 Hldgs %
47.84%
Holding
319
New
22
Increased
148
Reduced
94
Closed
14

Sector Composition

Rank Sector Weight
1 Technology 12.77%
2 Healthcare 7.71%
3 Financials 5.22%
4 Industrials 4.55%
5 Communication Services 2.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CLM icon
276
Cornerstone Strategic Value Fund
CLM
$2.22B
$188K 0.01%
24,525
+1,308
+6% +$10.2K
CGBD icon
277
Carlyle Secured Lending
CGBD
$694M
$150K 0.01%
+11,034
New +$162K
ADMA icon
278
ADMA Biologics
ADMA
$1.96B
$150K 0.01%
45,267
-8,047
-15% -$27.8K
HBAN icon
279
Huntington Bancshares
HBAN
$34.4B
$149K 0.01%
13,305
CRF
280
Cornerstone Total Return Fund
CRF
$1.16B
$138K 0.01%
18,981
+1,008
+6% +$7.48K
INVA icon
281
Innoviva
INVA
$1.55B
$137K 0.01%
12,212
+1,078
+10% +$13.1K
VLY icon
282
Valley National Bancorp
VLY
$7.9B
$134K 0.01%
14,500
TCPC icon
283
BlackRock TCP Capital
TCPC
$273M
$131K 0.01%
+12,731
New +$154K
GLAD icon
284
Gladstone Capital
GLAD
$422M
$130K 0.01%
+6,914
New +$138K
VBIV
285
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$88.8K ﹤0.01%
9,768
+89
+0.9% +$1.26K
ISPC icon
286
iSpecimen
ISPC
$2.72M
$87.9K ﹤0.01%
82
NAK
287
Northern Dynasty Minerals
NAK
$784M
$76.2K ﹤0.01%
318,950
VOR icon
288
Vor Biopharma
VOR
$1.15B
$73.3K ﹤0.01%
681
+138
+25% +$15.3K
NOK icon
289
Nokia
NOK
$51B
$67.1K ﹤0.01%
+13,668
New +$64.4K
MRSN
290
DELISTED
Mersana Therapeutics
MRSN
$64.1K ﹤0.01%
624
+13
+2% +$1.82K
HRTX icon
291
Heron Therapeutics
HRTX
$93.9M
$56.9K ﹤0.01%
37,698
+21,938
+139% +$54.9K
RBBN icon
292
Ribbon Communications
RBBN
$377M
$34.3K ﹤0.01%
10,030
FUBO icon
293
FuboTV Inc
FUBO
$261M
$12.1K ﹤0.01%
833
OTLK icon
294
Outlook Therapeutics
OTLK
$183M
$10.9K ﹤0.01%
500
RGLS
295
DELISTED
Regulus Therapeutics
RGLS
$8.78K ﹤0.01%
+10,363
New +$13.7K
CBOE icon
296
Cboe Global Markets
CBOE
$32.5B
-2,430
Closed -$305K
ELV icon
297
Elevance Health
ELV
$81.5B
-428
Closed -$220K
EXC icon
298
Exelon
EXC
$47.2B
-4,724
Closed -$204K
GBDC icon
299
Golub Capital BDC
GBDC
$3.34B
-11,901
Closed -$157K
IGV icon
300
iShares Expanded Tech-Software Sector ETF
IGV
$13.8B
-94,015
Closed -$4.81M

Similar funds

Grimes & Company's Q1 2023 Portfolio in Review

As of Q1 2023, Grimes & Company held 319 positions worth $2.44B, up 3% from $2.37B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Grimes & Company's Q1 2023 filing shows 22 new, 148 increased, 94 reduced and 14 closed positions. Its largest new stake was State Street SPDR Bloomberg Short Term High Yield Bond ETF: 6,195,592 shares worth $154M. The largest sale was JPMorgan Ultra-Short Income ETF, an estimated $349M.

By sector, the portfolio is most concentrated in Technology at 13% of assets, up from 10% a quarter earlier, followed by Healthcare and Financials.

  • Grimes & Company's largest Q1 2023 buy was State Street SPDR Bloomberg Short Term High Yield Bond ETF: 6,195,592 shares worth $154M.
  • Grimes & Company added most to iShares Core MSCI EAFE ETF in Q1 2023, an estimated $225M increase.
  • Grimes & Company's biggest Q1 2023 reduction was JPMorgan Ultra-Short Income ETF, cutting an estimated $349M.
  • Grimes & Company fully exited SVB Financial Group in Q1 2023, selling an estimated $5.35M.
  • Grimes & Company's ten largest holdings make up 48% of its $2.44B portfolio in Q1 2023.
  • Grimes & Company opened 22 new positions and closed 14 in Q1 2023.
  • Grimes & Company's portfolio value rose 3% quarter-over-quarter to $2.44B.

Based on Grimes & Company's 13F filing for Q1 2023, filed 20 Apr 2023.